<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334902</url>
  </required_header>
  <id_info>
    <org_study_id>HR-MPD-01</org_study_id>
    <nct_id>NCT04334902</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images</brief_title>
  <official_title>An Open Label, Multicenter, Retrospective, Pivotal Trial to Evaluate the Efficacy of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heuron Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heuron Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      mPDia is a software that has been pre-learned based on a neurodegenerative parkinsonism
      diagnosis model using Nigrosome 1 MRI images, and clinical decision support system for
      diagnosing neurodegenerative parkinsonism by automatically analyzing Nigrosome 1 MRI images
      by assisting the medical team.

      The specific aims of this study are to evaluate efficacy of mPDia for neurodegenerative
      Parkinsonism compared to the sensitivity and specificity levels of 18F FP-CIT PET/CT which is
      currently used to diagnose neurodegenerative parkinsonism.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of mPDia</measure>
    <time_frame>Within 4 weeks after collecting data</time_frame>
    <description>Sensitivity and specificity of mPDia in diagnosis of neurodegenerative parkinsonism based on golden standards</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">221</enrollment>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Abnormal</arm_group_label>
    <description>The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mPDia</intervention_name>
    <description>Clinical decision support system for diagnosing neurodegenerative parkinsonism</description>
    <arm_group_label>Abnormal</arm_group_label>
    <arm_group_label>Normal</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        (1) Adults over 19 years old (2) 3T nigrosome 1 MRI acquired (3) 18F FP-CIT PET/CT are
        confirmed to be normal(normal cohort) or abnormal(abnormal cohort)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria(Normal cohort):

          -  Adults over 19 years old

          -  3T nigrosome 1 MRI acquired

          -  18F FP-CIT PET/CT are confirmed to be normal

          -  The person who visits parkinsonism symptoms but is not or is normal for
             neurodegenerative parkinsonism

        Inclusion Criteria(Abnormal cohort):

          -  Adults over 19 years old

          -  3T nigrosome 1 MRI acquired

          -  18F FP-CIT PET/CT are confirmed to be abnormal

          -  The person who visits parkinsonism symptoms and has been diagnosed with
             neurodegenerative parkinsonism

        Exclusion Criteria:

          -  Patients with other brain diseases except parkinsonism

          -  Who have anatomical abnormality in MRIs etc.

          -  Who have other causes of tremor(e.g., thyroid disease)

          -  Patients with lesion in basal ganglia(e.g., vascular parkinsonism, hydrocephalus and
             Wilson's disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YoungHee Sung, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YoungHee Sung, M.D, Ph.D</last_name>
    <phone>+82-32-460-3346</phone>
    <email>atmann02@gilhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cha Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurodegenerative Parkinsonism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

